| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.;Liu T.-H.;Yau T.;Chiun Hsu; Dong Y.; Liu T.-H.; Yau T.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.;Yang T.-S.;Yen C.-J.;Cheng R.;Liu J.;Chiun Hsu; Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-18T09:11:58Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
YI-PING HUNG; YU-YUN SHAO; Chiun Hsu; CHIH-HUNG HSU; Lee, Jan Mou; Yang, Muh Hwa; Chao, Yee |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
